Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
- Conditions
- Colorectal CancerHead and Neck Squamous Cell CarcinomaGastrointestinal Stromal TumorsEsophageal SCCNon-small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04000529
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
- Conditions
- Bronchial AsthmaAsthmaAsthma, BronchialEosinophiliaPhysiological Effects of Drugs
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03989635
Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT03988608
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 467
- Registration Number
- NCT03988634
- Locations
- 🇺🇸
Boston Univeristy Medical Center ., Boston, Massachusetts, United States
🇺🇸Colorado Heart and Vascular ., Lakewood, Colorado, United States
🇺🇸Swedish Medical Ctr Cardiovascular Re, Seattle, Washington, United States
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03977649
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Pediatric Long-Term Follow-up and Rollover Study
- Conditions
- Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytomaOligodendroglioma, ChildhoodAnaplastic OligodendrogliomaGlioblastomaPilocytic AstrocytomaGiant Cell AstrocytomaPleomorphic XanthoastrocytomaAnaplastic Pleomorphic Xanthoastrocytoma
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 164
- Registration Number
- NCT03975829
- Locations
- 🇺🇸
Phoenix Children s Hospital, Phoenix, Arizona, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Nicklaus Childrens Hospital, Miami, Florida, United States
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT03968419
- Locations
- 🇺🇸
University of Kansas Medical Center Neurology Dept., Kansas City, Kansas, United States
🇺🇸Methodist Hospital / Methodist Cancer Center, Houston, Texas, United States
🇺🇸UCLA Oncology Hematology, La Jolla, California, United States
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
- Conditions
- Diffuse Large B-cell LymphomaLarge B-cell LymphomaAcute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Biological: Rapcabtagene autoleucel single agent
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT03960840
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- Conditions
- C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT03955445
- Locations
- 🇺🇸
Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
🇺🇸University of Iowa Health Care, Iowa City, Iowa, United States
🇺🇸Col Uni Med Center New York Presby, New York, New York, United States
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
- Conditions
- Age-Related Macular DegenerationWet Macular DegenerationMacular DegenerationRetinal DiseasesEye DiseasesRetinal Degeneration
- Interventions
- Biological: brolucuzumab 6 mg IVT
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT03954626
- Locations
- 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico